CHC in African Americans shows a more favorable course
characterized by lower serum ALT level, less inflammation on
biopsies, less trend to progress to cirrhosis, but a greater than
threefold higher risk of HCC as compared with whites.
African Americans have lower SVR when treated with
PegIFN/RBV (Jeffers 2004). In WIN-R trial, African Americans
have a significant higher SVR when treated with PegIFN alfa-2b
and weight-based RBV doses ranging between 800 and 1400
mg/day as compared with fixed RBV dose of 800 mg/day (21% vs.
10%, p=0.004) (Jacobson 2004). Despite advances in HCV therapy,
African Americans have decreased SVR with PegIFN/RBV, even
when optimized dosing is used and this may be explained partly
by the high distribution of unfavorable genetic predictors of SVR
(such as genotype 1 (McHutchison 2000) and unfavorable allele
CT and TT of IL28B (Ge 2009) as compared with other ethnic
groups
characterized by lower serum ALT level, less inflammation on
biopsies, less trend to progress to cirrhosis, but a greater than
threefold higher risk of HCC as compared with whites.
African Americans have lower SVR when treated with
PegIFN/RBV (Jeffers 2004). In WIN-R trial, African Americans
have a significant higher SVR when treated with PegIFN alfa-2b
and weight-based RBV doses ranging between 800 and 1400
mg/day as compared with fixed RBV dose of 800 mg/day (21% vs.
10%, p=0.004) (Jacobson 2004). Despite advances in HCV therapy,
African Americans have decreased SVR with PegIFN/RBV, even
when optimized dosing is used and this may be explained partly
by the high distribution of unfavorable genetic predictors of SVR
(such as genotype 1 (McHutchison 2000) and unfavorable allele
CT and TT of IL28B (Ge 2009) as compared with other ethnic
groups
No comments:
Post a Comment